Jaume Mora Graupera
Jefe de Grupo Senior
Research group
Professional network profiles
Last Publications
- Prada-Varela E, Táboas-Outón P, Andrades E, Gomez-Gonzalez S, Mateo-Lozano S, Cebrià A, Berenguer-Molins P, Perera-Bel J, Arcon JP, Saen-Oon S, Díaz L, Gay M, Folch-I-Casanovas I, Odena A, Vilaseca M, Rovira Q, García-Gerique L, Rodriguez E, Rovira-Zurriaga C, Rodrigues G, Carcaboso AM, Avgustinova A, Hernandez-Muñoz MI and Mora J PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma. NATURE COMMUNICATIONS . 16(1): 9816-9816.
- Hernandez-Muñoz MI, Cuervas I, Prada-Varela E, Pulecio J, Gimeno R, Andrades E, Gomez-Gonzalez S, Berenguer-Molins P, Acedo-Terrades A, Perera-Bel J, Bódalo-Torruella M, Nonell L, Pérez E, Grases D, Mata C, Yélamos J, Richaud-Patin Y, Vidal E, Cuartero Y, Le Dily F, Suñol M, Manzanares-Quintela A, Raya A and Mora J EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma. NATURE COMMUNICATIONS . 16(1): 9427-9427.
- Palmerini E, Meazza C, Tamburini A, Márquez-Vega C, Bisogno G, Fagioli F, Ferraresi V, Milano GM, Coccoli L, Rubio-San-Simón A, Gallego O, Llinares Riestra ME, Manzitti C, Mora J, Vaz-Salgado MÁ, Luksch R, Mata C, Pierini M, Carretta E, Cesari M, Paioli A, Marrari A, Scotlandi K, Serra M, Asaftei SD, Gambarotti M, Picci P, Ferrari S, Valverde C, Ibrahim T and Broto JM Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials JOURNAL OF CLINICAL ONCOLOGY . 43(28): 3113-3122.
Projects
- Project name:
- FIGH4MB_Establishment of the first preclinical genetic mouse models of Group 4 Medulloblastoma.
- Leader
- Jaume Mora Graupera
- Funding entities:
- Fight Kids Cancer
- Code
- PFE00151
- Starting - finishing date:
- 2025 - 2028
- Project name:
- ADVANCED THERAPIES (RICORS-TERAV)
- Leader
- Susana Rives Solà
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- RD24/0014/0006
- Starting - finishing date:
- 2025 - 2027
- Project name:
- Disrupción de enhancers: la nueva generación de terapia epigenética en el sarcoma de Ewing
- Leader
- Jaume Mora Graupera, Sara Sánchez Molina
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI24/00804
- Starting - finishing date:
- 2025 - 2027
News
-
Dr. Jaume Mora receives the IV FERO Dr. Baselga Grant to promote new therapies against pediatric cancer
The scientific director of the Pediatric Cancer Center Barcelona receives a grant of €300,000 for a three-year project aimed at developing more effective and less toxic treatments for childhood cancer.
-
A study led by SJD identifies new therapeutic targets for Ewing sarcoma
The study identifies the demethylases KDM6A and KDM6B as essential collaborators of the fusion protein EWSR1::FLI1, responsible for the epigenetic reprogramming that drives tumor growth.
-
The Josep Carreras Foundation and Sant Joan de Déu Create a Childhood Leukemia Research Program Worth Over 10 Million Euros
The Josep Carreras Foundation (FJC), the Josep Carreras Leukemia Research Institute (IJC), and the Sant Joan de Déu Research Institute (IRSJD) have agreed to develop a joint research program on childhood leukemia valued at over 10 million euros.
More activities
-
Defensa tesi doctoral: Pablo Táboas Outón
Auditori Plaza · Hospital Sant Joan de Déu and online
-
Defensa tesi doctoral: Irene Cuervas Oliveras
Auditori Plaza · Hospital Sant Joan de Déu
-
Defensa tesi doctoral: María Sánchez Jiménez
Auditori Plaza · Hospital Sant Joan de Déu and online
